307 related articles for article (PubMed ID: 11978643)
1. Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male zucker diabetic fatty rats.
Sudre B; Broqua P; White RB; Ashworth D; Evans DM; Haigh R; Junien JL; Aubert ML
Diabetes; 2002 May; 51(5):1461-9. PubMed ID: 11978643
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats.
Balkan B; Kwasnik L; Miserendino R; Holst JJ; Li X
Diabetologia; 1999 Nov; 42(11):1324-31. PubMed ID: 10550416
[TBL] [Abstract][Full Text] [Related]
3. (2S,4S)-4-Fluoro-1-{[(2-hydroxy-1,1-dimethylethyl)amino]acetyl}-pyrrolidine-2-carbonitrile monobenzenesulfonate (TS-021) is a selective and reversible dipeptidyl peptidase IV inhibitor.
Tajima A; Yamamoto K; Kozakai A; Okumura-Kitajima L; Mita Y; Kitano K; Jingu S; Nakaike S
Eur J Pharmacol; 2011 Mar; 655(1-3):99-107. PubMed ID: 21262219
[TBL] [Abstract][Full Text] [Related]
4. KR-62436, 6-{2-[2-(5-cyano-4,5-dihydropyrazol-1-yl)-2-oxoethylamino]ethylamino}nicotinonitrile, is a novel dipeptidyl peptidase-IV (DPP-IV) inhibitor with anti-hyperglycemic activity.
Kim KR; Rhee SD; Kim HY; Jung WH; Yang SD; Kim SS; Ahn JH; Cheon HG
Eur J Pharmacol; 2005 Jul; 518(1):63-70. PubMed ID: 16106524
[TBL] [Abstract][Full Text] [Related]
5. A novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial hyperglycemia and dyslipidemia after single and repeated administrations.
Fukuda-Tsuru S; Anabuki J; Abe Y; Yoshida K; Ishii S
Eur J Pharmacol; 2012 Dec; 696(1-3):194-202. PubMed ID: 23022337
[TBL] [Abstract][Full Text] [Related]
6. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats.
Pospisilik JA; Martin J; Doty T; Ehses JA; Pamir N; Lynn FC; Piteau S; Demuth HU; McIntosh CH; Pederson RA
Diabetes; 2003 Mar; 52(3):741-50. PubMed ID: 12606516
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological profile of ASP8497, a novel, selective, and competitive dipeptidyl peptidase-IV inhibitor, in vitro and in vivo.
Someya Y; Tahara A; Nakano R; Matsuyama-Yokono A; Nagase I; Fukunaga Y; Takasu T; Hayakawa M; Shibasaki M
Naunyn Schmiedebergs Arch Pharmacol; 2008 May; 377(3):209-17. PubMed ID: 18398600
[TBL] [Abstract][Full Text] [Related]
8. 7-But-2-ynyl-9-(6-methoxy-pyridin-3-yl)-6-piperazin-1-yl-7,9-dihydro-purin-8-one is a novel competitive and selective inhibitor of dipeptidyl peptidase IV with an antihyperglycemic activity.
Yamazaki K; Yasuda N; Inoue T; Nagakura T; Kira K; Shinoda M; Saeki T; Tanaka I
J Pharmacol Exp Ther; 2006 Dec; 319(3):1253-7. PubMed ID: 16980568
[TBL] [Abstract][Full Text] [Related]
9. Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs.
Deacon CF; Wamberg S; Bie P; Hughes TE; Holst JJ
J Endocrinol; 2002 Feb; 172(2):355-62. PubMed ID: 11834453
[TBL] [Abstract][Full Text] [Related]
10. Degradation and glycemic effects of His(7)-glucitol glucagon-like peptide-1(7-36)amide in obese diabetic ob/ob mice.
O'Harte FP; Mooney MH; Kelly CM; McKillop AM; Flatt PR
Regul Pept; 2001 Jan; 96(3):95-104. PubMed ID: 11111014
[TBL] [Abstract][Full Text] [Related]
11. Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice.
Reimer MK; Holst JJ; Ahrén B
Eur J Endocrinol; 2002 May; 146(5):717-27. PubMed ID: 11980629
[TBL] [Abstract][Full Text] [Related]
12. Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice.
Ahrén B; Holst JJ; Mårtensson H; Balkan B
Eur J Pharmacol; 2000 Sep; 404(1-2):239-45. PubMed ID: 10980284
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes.
Holst JJ; Deacon CF
Diabetes; 1998 Nov; 47(11):1663-70. PubMed ID: 9792533
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the antidiabetic effects of dipeptidyl peptidase-IV inhibitor ASP8497 in streptozotocin-nicotinamide-induced mildly diabetic mice.
Tahara A; Matsuyama-Yokono A; Nakano R; Someya Y; Hayakawa M; Shibasaki M
Pharmacology; 2009; 83(3):177-87. PubMed ID: 19176982
[TBL] [Abstract][Full Text] [Related]
15. A novel long acting DPP-IV inhibitor PKF-275-055 stimulates β-cell proliferation resulting in improved glucose homeostasis in diabetic rats.
Akarte AS; Srinivasan BP; Gandhi S
Biochem Pharmacol; 2012 Jan; 83(2):241-52. PubMed ID: 22015634
[TBL] [Abstract][Full Text] [Related]
16. Acute and chronic effects of the incretin enhancer vildagliptin in insulin-resistant rats.
Burkey BF; Li X; Bolognese L; Balkan B; Mone M; Russell M; Hughes TE; Wang PR
J Pharmacol Exp Ther; 2005 Nov; 315(2):688-95. PubMed ID: 16027230
[TBL] [Abstract][Full Text] [Related]
17. Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A.
Oeseburg H; de Boer RA; Buikema H; van der Harst P; van Gilst WH; Silljé HH
Arterioscler Thromb Vasc Biol; 2010 Jul; 30(7):1407-14. PubMed ID: 20448207
[TBL] [Abstract][Full Text] [Related]
18. Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo.
Kim JG; Baggio LL; Bridon DP; Castaigne JP; Robitaille MF; Jetté L; Benquet C; Drucker DJ
Diabetes; 2003 Mar; 52(3):751-9. PubMed ID: 12606517
[TBL] [Abstract][Full Text] [Related]
19. Dipeptidyl peptidase IV inhibitor NVP-DPP728 ameliorates early insulin response and glucose tolerance in aged rats but not in aged Fischer 344 rats lacking its enzyme activity.
Mitani H; Takimoto M; Kimura M
Jpn J Pharmacol; 2002 Apr; 88(4):451-8. PubMed ID: 12046989
[TBL] [Abstract][Full Text] [Related]
20. Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats.
Liu WJ; Xie SH; Liu YN; Kim W; Jin HY; Park SK; Shao YM; Park TS
J Pharmacol Exp Ther; 2012 Feb; 340(2):248-55. PubMed ID: 22025647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
